CDK1/CDK2 inhibitors (Boehringer Ingelheim)

N/A

Report date: 2026/01/06 15:22:14
NME

Base Information

Drug NameCDK1/CDK2 inhibitors (Boehringer Ingelheim)
Drug Alias Namecyclin-dependent kinase inhibitors (Boehringer Ingelheim)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 1 inhibitorsCyclin-dependent kinase 2 inhibitors
TargetsCyclin-dependent kinase 1Cyclin-dependent kinase 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustria
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A